SNRPD1 and breast carcinoma: Patients with high SNRPD1 expression have poorer RFS as compared with those harboring low SNRPD1 expression (1010 patients, HR = 1.56, p<0.0001 for 10 years), and such a survival disadvantage vanished after receiving chemotherapies (602 patients, HR=1.21, p>0.05 for 10 years, Fig. 5A), suggestive of the role of SNRPD1 in sensitizing breast cancer cells to chemotherapies.